amhsr-open access medicla research journals

Interactions of Rosiglitazone and Anti‑Arrhythmic Drugs in Animal Model


Mohammed YM, Mohammed EI, Mohiuddin N, Syeda SS

Background: Diabetes increases the risk of vascular problems by two times compared with a healthy individual, with deposition of fats in blood vessel and this includes cardiovascular disease. The treatment regimens for patients suffering from both diseases generally include prolonged use of antiâÂ??Â??diabetic drugs for diabetes and antiâÂ??Â??arrhythmic drugs for cardiac arrhythmias. Aim: The aim of the study is to compare the influence of Mexiletine and Disopyramide on the pharmacodynamics (PDs) of Rosiglitazone in normal and diabetic rats. Materials and Methods: The study was conducted in normal rats and diabetic induced rats (with Alloxan monohydrate 100 mg/kg body weight). Albino rats weighing between 160 and 280 g were administered oral doses of Rosiglitazone 0.72 mg/kg, Mexiletine 36 mg/kg, or Disopyramide 18 mg/kg of bodyweight and their combination, with 1 week of washout between treatments. Eighteen rats were divided into three subâÂ??Â??sets with six rats in each subâÂ??Â??set. After 4 days, the blood glucose was estimated to confirm the diabetes. The Analysis of Covariance (ANCOVA) using MedCalc® software Version was performed to analyze mean change in blood glucose between treatments with body weight as coâÂ??Â??variable and treatment as factor for normal and diabetic rats. Results: No statistically significant difference in mean change in blood glucose between Rosiglitazone in comparison with Rosiglitazone + Mexiletine or Rosiglitazone + Disopyramide was observed in normal and diabetic rats (P = 0.606). The maximum mean change in blood glucose for Rosiglitazone and Rosiglitazone + Mexiletine or Rosiglitazone + Disopyramide was observed at 1 h and 8 h in normal and diabetic rats. The post hoc analysis showed baseline correction method has increased the reliability of the results (P < 0.001). Conclusion: The study concludes that PD activity of Rosiglitazone was not affected by the antiâÂ??Â??arrhythmic drugs. This study introduced a new statistical methodology for analyzing the blood glucose endpoint.

Select your language of interest to view the total content in your interested language

Awards Nomination
20+ Million Readerbase
Abstracted/Indexed in

  • Include Baidu Scholar
  • CNKI (China National Knowledge Infrastructure)
  • EBSCO Publishing's Electronic Databases
  • Exlibris – Primo Central
  • Google Scholar
  • Hinari
  • Infotrieve
  • National Science Library
  • ProQuest
  • TdNet
  • African Index Medicus
Annals of Medical and Health Sciences Research The Annals of Medical and Health Sciences Research is a bi-monthly multidisciplinary medical journal.
Submit your Manuscript